Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
32 studies found for:    " June 25, 2008":" July 25, 2008"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Show Display Options
RSS Create an RSS feed from your search for:
" June 25, 2008":" July 25, 2008"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed Lovastatin: Immunomodulatory Value Evaluation
Condition: HIV Seropositivity
Interventions: Drug: Lovastatin;   Other: placebo
2 Active, not recruiting
Has Results
Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir
Condition: HIV Infection
Interventions: Drug: Elvitegravir;   Drug: Raltegravir;   Drug: Placebo to match elvitegravir;   Drug: Placebo to match raltegravir;   Drug: Background regimen
3 Completed
Has Results
Safety and Efficacy Study of Switching From Epzicom to Truvada
Condition: HIV Infection
Interventions: Drug: emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF);   Drug: abacavir (ABC)/lamivudine (3TC)
4 Completed Cohort Study of HIV-1 Incidence Among Clients of the Thai Red Cross AIDS Research Center, Bangkok, Thailand
Condition: HIV Infections
Intervention:
5 Unknown  Repeated DermaVir Immunizations in HIV-1 Infected Treatment-naïve Patients
Condition: HIV Infection
Interventions: Biological: DermaVir;   Biological: Placebo
6 Completed
Has Results
Single DermaVir Immunization in HIV-1 Infected Patients on HAART
Condition: HIV Infection
Interventions: Biological: DermaVir;   Drug: HAART
7 Completed Clinical Trial Assessing Once Daily Raltegravir Administration (800 mg QD) in HIV-1-Infected Patients Receiving Unboosted Atazanavir (400 mg QD)- Based Antiretroviral Therapy
Condition: HIV Infections
Intervention: Drug: Addition of raltegravir 800 mg QD to HAART
8 Active, not recruiting Effectiveness of Antiretroviral Therapy During Acute HIV Infection
Condition: HIV Infections
Interventions: Drug: Highly Active Antiretroviral Therapy (HAART);   Other: No treatment
9 Active, not recruiting Intervention for (Those) Recently Informed of Seropositive Status (IRISS)
Condition: HIV Infections
Interventions: Behavioral: Skills-Building Intervention;   Behavioral: Personal Interview Group
10 Completed Effectiveness of a Community-level HIV/STD Prevention Intervention in Promoting Safer Sexual Behaviors in High-risk Populations
Conditions: HIV Infections;   Sexually Transmitted Diseases
Interventions: Behavioral: Community Popular Opinion Leader (C-POL);   Behavioral: HIV/STD educational materials
11 Completed Healthy Activities for Prize Incentives
Conditions: Substance Abuse;   HIV Infections
Intervention: Behavioral: contingency management
12 Completed Family Centered Advanced Care Planning for Adolescents With HIV/AIDS and Their Families
Condition: HIV Infections
Interventions: Behavioral: Family Centered Advanced Care Planning (FCACP) sessions;   Behavioral: Health education control sessions
13 Completed Phase I Study of HIV Adenoviral Vector Vaccine in Healthy Subjects Using Needle or Biojector Injection
Condition: HIV Infections
Intervention: Drug: VRC-HIVADV014-00-VP
14 Completed Impact of an HPV Vaccine in HIV-Infected Young Women
Condition: HIV Infection
Intervention: Biological: HPV vaccine for strains -6, -11, -16, and -18
15 Completed Establishing Normal Values for Neuropsychological Testing in HIV-negative Thais
Condition: HIV Infections
Intervention:
16 Enrolling by invitation Cerebrospinal Fluid (CSF) Raltegravir Substudy
Condition: HIV Infections
Intervention:
17 Completed Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine in HIV-positive Adults.
Condition: Tuberculosis (TB)
Interventions: Biological: GSK's candidate Mycobacterium tuberculosis vaccine 692342;   Biological: Control vaccine with the adjuvant system.;   Biological: Control vaccine with physiological saline
18 Withdrawn Directly Administered Antiretroviral Therapy (DAART) Among HIV-1infected Injecting Drug Users (IDUs) in Chennai, India
Conditions: HIV Infections;   Heroin Dependence
Interventions: Behavioral: Directly Administered Antiretroviral Therapy (DAART);   Behavioral: SAT
19 Unknown  Social-Psychological Intervention to Improve Adherence to HAART
Conditions: AIDS;   HIV Infections
Interventions: Behavioral: Social-psycho intervention to improve adherence to HAART;   Other: Usual care
20 Completed
Has Results
Adding Maraviroc to Antiretroviral Therapy for Suboptimal CD4 T-Cell Recovery Despite Sustained Virologic Suppression
Condition: HIV Infections
Intervention: Drug: Maraviroc

   Previous Page Studies Shown (1-20) Next Page (21-32) Show next page of results    Last Page
Indicates status has not been verified in more than two years